Age-related macular degeneration: Review of current treatments

Preeti R. Poley, William M. Stapleton, Fang Qui, Michael L. Mulhern, David D. Ingvoldstad, Eyal Margalit

Research output: Contribution to journalReview article

Abstract

The pathogenesis of choroidal neovascular membrane in neovascular age-related macular degeneration (AMD) is multifactorial and involves angiogenesis, inflammation and other yet to be discovered entities. The role of angiogenesis in this disease process has been exploited, and at present forms the basis of the most successful therapy. Ranibizumab is a nonselective antibody fragment found to not only maintain vision, but also improve vision when compared with sham injections and photodynamic therapy treatments. Bevacizumab, with a similar mechanism of action as ranibizumab, although not US FDA approved for intravitreal use, is being used with promising results of decreased vision and loss of foveal thickness in neovascular AMD. Several studies are underway, including those involving comparing ranibizumab and bevacizumab, and trials involving brachytherapy, sirolimus and topical mecamylamine, in the hope of tackling AMD by addressing its multiple contributing etiologies.

Original languageEnglish (US)
Pages (from-to)195-201
Number of pages7
JournalExpert Review of Ophthalmology
Volume6
Issue number2
DOIs
StatePublished - Apr 1 2011

Fingerprint

Photodynamic therapy
Macular Degeneration
Antibodies
Membranes
Mecamylamine
Immunoglobulin Fragments
Brachytherapy
Photochemotherapy
Sirolimus
Therapeutics
Inflammation
Injections
Ranibizumab
Bevacizumab

Keywords

  • anti-vascular endothelial growth factor
  • bevacizumab
  • dry macular degeneration
  • ranibizumab
  • wet macular degeneration

ASJC Scopus subject areas

  • Biomedical Engineering
  • Ophthalmology
  • Optometry

Cite this

Poley, P. R., Stapleton, W. M., Qui, F., Mulhern, M. L., Ingvoldstad, D. D., & Margalit, E. (2011). Age-related macular degeneration: Review of current treatments. Expert Review of Ophthalmology, 6(2), 195-201. https://doi.org/10.1586/eop.11.6

Age-related macular degeneration : Review of current treatments. / Poley, Preeti R.; Stapleton, William M.; Qui, Fang; Mulhern, Michael L.; Ingvoldstad, David D.; Margalit, Eyal.

In: Expert Review of Ophthalmology, Vol. 6, No. 2, 01.04.2011, p. 195-201.

Research output: Contribution to journalReview article

Poley, PR, Stapleton, WM, Qui, F, Mulhern, ML, Ingvoldstad, DD & Margalit, E 2011, 'Age-related macular degeneration: Review of current treatments', Expert Review of Ophthalmology, vol. 6, no. 2, pp. 195-201. https://doi.org/10.1586/eop.11.6
Poley PR, Stapleton WM, Qui F, Mulhern ML, Ingvoldstad DD, Margalit E. Age-related macular degeneration: Review of current treatments. Expert Review of Ophthalmology. 2011 Apr 1;6(2):195-201. https://doi.org/10.1586/eop.11.6
Poley, Preeti R. ; Stapleton, William M. ; Qui, Fang ; Mulhern, Michael L. ; Ingvoldstad, David D. ; Margalit, Eyal. / Age-related macular degeneration : Review of current treatments. In: Expert Review of Ophthalmology. 2011 ; Vol. 6, No. 2. pp. 195-201.
@article{19291f48684343f0bad6fd742e0a56ef,
title = "Age-related macular degeneration: Review of current treatments",
abstract = "The pathogenesis of choroidal neovascular membrane in neovascular age-related macular degeneration (AMD) is multifactorial and involves angiogenesis, inflammation and other yet to be discovered entities. The role of angiogenesis in this disease process has been exploited, and at present forms the basis of the most successful therapy. Ranibizumab is a nonselective antibody fragment found to not only maintain vision, but also improve vision when compared with sham injections and photodynamic therapy treatments. Bevacizumab, with a similar mechanism of action as ranibizumab, although not US FDA approved for intravitreal use, is being used with promising results of decreased vision and loss of foveal thickness in neovascular AMD. Several studies are underway, including those involving comparing ranibizumab and bevacizumab, and trials involving brachytherapy, sirolimus and topical mecamylamine, in the hope of tackling AMD by addressing its multiple contributing etiologies.",
keywords = "anti-vascular endothelial growth factor, bevacizumab, dry macular degeneration, ranibizumab, wet macular degeneration",
author = "Poley, {Preeti R.} and Stapleton, {William M.} and Fang Qui and Mulhern, {Michael L.} and Ingvoldstad, {David D.} and Eyal Margalit",
year = "2011",
month = "4",
day = "1",
doi = "10.1586/eop.11.6",
language = "English (US)",
volume = "6",
pages = "195--201",
journal = "Expert Review of Ophthalmology",
issn = "1746-9899",
number = "2",

}

TY - JOUR

T1 - Age-related macular degeneration

T2 - Review of current treatments

AU - Poley, Preeti R.

AU - Stapleton, William M.

AU - Qui, Fang

AU - Mulhern, Michael L.

AU - Ingvoldstad, David D.

AU - Margalit, Eyal

PY - 2011/4/1

Y1 - 2011/4/1

N2 - The pathogenesis of choroidal neovascular membrane in neovascular age-related macular degeneration (AMD) is multifactorial and involves angiogenesis, inflammation and other yet to be discovered entities. The role of angiogenesis in this disease process has been exploited, and at present forms the basis of the most successful therapy. Ranibizumab is a nonselective antibody fragment found to not only maintain vision, but also improve vision when compared with sham injections and photodynamic therapy treatments. Bevacizumab, with a similar mechanism of action as ranibizumab, although not US FDA approved for intravitreal use, is being used with promising results of decreased vision and loss of foveal thickness in neovascular AMD. Several studies are underway, including those involving comparing ranibizumab and bevacizumab, and trials involving brachytherapy, sirolimus and topical mecamylamine, in the hope of tackling AMD by addressing its multiple contributing etiologies.

AB - The pathogenesis of choroidal neovascular membrane in neovascular age-related macular degeneration (AMD) is multifactorial and involves angiogenesis, inflammation and other yet to be discovered entities. The role of angiogenesis in this disease process has been exploited, and at present forms the basis of the most successful therapy. Ranibizumab is a nonselective antibody fragment found to not only maintain vision, but also improve vision when compared with sham injections and photodynamic therapy treatments. Bevacizumab, with a similar mechanism of action as ranibizumab, although not US FDA approved for intravitreal use, is being used with promising results of decreased vision and loss of foveal thickness in neovascular AMD. Several studies are underway, including those involving comparing ranibizumab and bevacizumab, and trials involving brachytherapy, sirolimus and topical mecamylamine, in the hope of tackling AMD by addressing its multiple contributing etiologies.

KW - anti-vascular endothelial growth factor

KW - bevacizumab

KW - dry macular degeneration

KW - ranibizumab

KW - wet macular degeneration

UR - http://www.scopus.com/inward/record.url?scp=79955066679&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79955066679&partnerID=8YFLogxK

U2 - 10.1586/eop.11.6

DO - 10.1586/eop.11.6

M3 - Review article

AN - SCOPUS:79955066679

VL - 6

SP - 195

EP - 201

JO - Expert Review of Ophthalmology

JF - Expert Review of Ophthalmology

SN - 1746-9899

IS - 2

ER -